14 completed, 5 recruiting, 1 not yet recruiting, 1 terminated. 4 Phase 1, 2 Early Phase 1, 2 Not applicable, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Early Phase 1 | 2 | Completed 2 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Progressive Supranuclear Palsy (PSP): new trials by email Literature Review of Progressive Supranuclear Palsy (PSP) trials Research Report on Progressive Supranuclear Palsy (PSP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes PARKINSON DISEASE (Disorder), Atypical Parkinsonism | Not yet recruiting | International Institute of Molecular and Cell Biology in Warsaw | 200 | 2026-06-04 | 2026-05-28 | |
| First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate - Progressive Supranuclear Palsy (PSP), Healthy Participants | Early Phase 1 | Completed | Invicro | 11 | 2025-11-17 | 2026-07-10 |
| Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH) We did not apply any interventions; only observational research was conducted. - Multiple System Atrophy, Dementia With Lewy Bodies (DLB) | Recruiting | Second Affiliated Hospital of Soochow University | 500 | 2025-11-12 | 2026-09-08 | |
| Art Therapy in Progressive Supranuclear Palsy Art Thrapy - Progressive Supranuclear Palsy(PSP), Progressive Supranuclear Palsy (PSP) | Not applicable | Completed | Baylor College of Medicine | 20 | 2025-01-14 | 2026-09-16 |
| The CurePSP Genetics Program Whole genome sequencing will be performed at the NIH - PSP, PSP - Progressive Supranuclear Palsy | Recruiting | Massachusetts General Hospital | 1000 | 2024-10-08 | 2026-01-14 | |
| Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT) - Neuromuscular Diseases, Obesity (Disorder) | Not applicable | Recruiting | Centre Hospitalier Universitaire de Liege | 300 | 2024-03-29 | 2025-08-22 |
| Synaptic Loss in Multiple System Atrophy Study procedures for MSA patients, Study procedures for PSP patients - Multiple System Atrophy, Progressive Supranuclear Palsy (PSP) | Recruiting | University of Exeter | 36 | 2021-09-01 | 2026-02-10 | |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP) | Recruiting | Mayo Clinic | 2100 | 2020-03-01 | 2026-10-07 | |
| Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 ABBV-8E12 - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | AbbVie | 3 | 2018-04-17 | 2019-12-03 |
| An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) ABBV-8E12, Placebo solution for IV infusion on Day 15 - Progressive Supranuclear Palsy (PSP) | Phase 2 | Terminated | AbbVie | 142 | 2018-01-24 | 2021-02-03 |
| Human CNS Tau Kinetics in Tauopathies 13C6 Leucine - Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) | Completed | Washington University School of Medicine | 27 | 2017-08-21 | 2022-04-13 | |
| ADDIA Proof-of-Performance Clinical Study volumetric MRI - Alzheimer Disease (AD), Frontotemporal Lobar Degeneration | Completed | Amoneta Diagnostics SAS | 821 | 2016-09-01 | 2024-09-19 | |
| Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Rivastigmine, Placebo - Progressive Supranuclear Palsy (PSP) | Phase 3 | Completed | Assistance Publique Hopitaux De Marseille | 106 | 2016-07-26 | 2023-07-20 |
| 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2 Observational Study - Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS) | Completed | University of California, San Francisco | 293 | 2016-01-01 | 2025-04-13 | |
| Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies [18F]MNI-815 (MNI-815) - Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP) | Early Phase 1 | Completed | Molecular NeuroImaging | 7 | 2015-05-01 | 2016-12-16 |
| PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration | Unknown | University College, London | 900 | 2014-10-01 | 2020-10-19 | |
| Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) FTLD, Progressive Supranuclear Palsy (PSP) | Completed | University of California, San Francisco | 1489 | 2014-09-01 | 2021-05-21 | |
| Safety Study of TPI-287 to Treat CBS and PSP TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS) | Phase 1 | Completed | University of California, San Francisco | 44 | 2014-05-01 | 2020-04-15 |
Showing 20 of 22. Sign in to see all of them.
Supranuclear Palsy, Progressive (22) · Corticobasal Degeneration (9) · Multiple System Atrophy (7) · Parkinson Disease (4) · Pick Disease of the Brain (4) · Tauopathies (4) · Alzheimer Disease (3) · Frontotemporal Dementia (3) · Frontotemporal Lobar Degeneration (3) · Lewy Body Disease (3) · Amyotrophic Lateral Sclerosis (2) · Color Vision Defects (2) · Parkinsonian Disorders (2) · Charcot-Marie-Tooth Disease (1) · Chronic Traumatic Encephalopathy (1)
Basal Ganglia Diseases (22) · Brain Diseases (22) · Central Nervous System Diseases (22) · Cranial Nerve Diseases (22) · Eye Diseases (22) · Movement Disorders (22) · Nervous System Diseases (22) · Neurodegenerative Diseases (22) · Neurologic Manifestations (22) · Ocular Motility Disorders (22) · Ophthalmoplegia (22) · Paralysis (22) · Pathological Conditions, Signs and Symptoms (22) · Signs and Symptoms (22) · Tauopathies (18)
tilavonemab (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Injections (1) · Iodine-123 (1) · Observation (1) · Oligonucleotides, Antisense (1) · Rivastigmine (1) · TPI-287 (1) · Walk Test (1) · florbetapir (1) · ioflupane (1)
University of California, San Francisco (3) · AbbVie (2) · Molecular NeuroImaging (2) · Amoneta Diagnostics SAS (1) · Assistance Publique Hopitaux De Marseille (1) · Baylor College of Medicine (1) · Centre Hospitalier Universitaire de Liege (1) · GE Healthcare (1) · International Institute of Molecular and Cell Biology in Warsaw (1) · Invicro (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Milton S. Hershey Medical Center (1) · Novartis Pharmaceuticals (1) · Second Affiliated Hospital of Soochow University (1)
United States (14) · Canada (5) · United Kingdom (3) · Belgium (2) · China (2) · France (2) · Italy (2) · Australia (1) · Germany (1) · Japan (1) · Poland (1) · Switzerland (1) · Turkey (Türkiye) (1)
Adam Boxer, MD, PhD (2) · Adam L Boxer, MD, PhD (2) · Danna Jennings, MD (2) · Adrian Ivanoiu, MD (1) · Audrey Gabelle, MD (1) · Bradley Boeve, MD (1) · Bruno Dubois, MD (1) · Chi-Ying Roy Lin, MD, MPH (1) · Chunfeng Liu (1) · Eloi Magnin, MD (1) · Florence Pasquier, MD (1) · Frisoni Giovanni, MD (1)
PMID 35790423, PMID 31710340, PMID 33827960, PMID 33894193, PMID 35492244, PMID 38578117, PMID 38959435, PMID 41389437
2016 (1), 2017 (1), R01AG038791 (1), U19AG063911 (1), U54NS092089 (1)